Patients who have received prior chemotherapy for unresectable disease 
Patients with any active or uncontrolled infection, including known HIV infection. (Patients with active hepatitis B will be placed on lamivudine. Patients with active hepatitis C will be eligible if liver tests qualify (5.1.9) 
Patients with psychiatric disorders that would interfere with consent or follow-up. Pregnant or lactating women. Men and women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. 
Patients with any other severe concurrent disease, which in the judgment of the investigator, would make the patient inappropriate for entry into this study.       
    

NCT00183885_exc_T1
Procedure
chemotherapy
NCT00183885_exc_T2
Condition
unresectable disease
NCT00183885_exc_T3
Qualifier
uncontrolled
NCT00183885_exc_T4
Qualifier
active
NCT00183885_exc_T5
Condition
infection
NCT00183885_exc_T6
Scope
active or uncontrolled
NCT00183885_exc_T7
Procedure
HIV infection
NCT00183885_exc_T8
Condition
hepatitis B
NCT00183885_exc_T9
Qualifier
active
NCT00183885_exc_T10
Scope
active hepatitis B
NCT00183885_exc_T11
Drug
lamivudine
NCT00183885_exc_T12
Condition
hepatitis C
NCT00183885_exc_T13
Qualifier
active
NCT00183885_exc_T14
Scope
active hepatitis C
NCT00183885_exc_T15
Measurement
liver tests
NCT00183885_exc_T16
Value
qualify
NCT00183885_exc_T17
Condition
psychiatric disorders
NCT00183885_exc_T18
Qualifier
interfere with consent
NCT00183885_exc_T19
Qualifier
interfere with follow-up
NCT00183885_exc_T20
Condition
Pregnant
NCT00183885_exc_T21
Condition
lactating
NCT00183885_exc_T22
Person
women
NCT00183885_exc_T23
Condition
reproductive potential
NCT00183885_exc_T24
Procedure
effective contraceptive method
NCT00183885_exc_T25
Qualifier
severe
NCT00183885_exc_T26
Condition
concurrent disease
NCT00183885_exc_T28
Observation
entry into this study
NCT00183885_exc_T29
Mood
inappropriate for